CDXC: Small Float Biopharma with BIG Potential $20
After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price.
The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin.
It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin.
It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。